Literature DB >> 27959471

Lumbar sympathectomy techniques for critical lower limb ischaemia due to non-reconstructable peripheral arterial disease.

Veena Kl Karanth1, Tulasi Kota Karanth2, Laxminarayan Karanth3.   

Abstract

BACKGROUND: Critical lower limb ischaemia (CLI) is a manifestation of peripheral arterial disease (PAD) that is seen in patients with typical chronic ischaemic rest pain or patients with ischaemic skin lesions - ulcers or gangrene - for longer than 2 weeks. Critical lower limb ischaemia is the most severe form of PAD, and interventions to improve arterial perfusion become necessary. Although surgical bypass has been the gold standard for revascularisation, the extent or the site of disease may be such that the artery cannot be reconstructed or bypassed. These patients require other modalities of treatment, for example, vasodilatation by drugs or lumbar sympathectomy to relieve pain at rest and to avoid amputations. A systematic review of randomised controlled trials is required to evaluate the effects of lumbar sympathectomy in treating patients with CLI due to non-reconstructable PAD.
OBJECTIVES: The objective of this review is to assess the effects of lumbar sympathectomy by open, laparoscopic and percutaneous methods compared with no treatment or compared with any other method of lumbar sympathectomy in patients with CLI due to non-reconstructable PAD. SEARCH
METHODS: The Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (January 2016) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 12). In addition, the CIS searched clinical trials databases for details of ongoing and unpublished studies. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing any of the treatment modalities of lumbar sympathectomy, such as open, laparoscopic and chemical percutaneous methods, with no treatment or with any other method of lumbar sympathectomy for CLI due to non-reconstructable PAD were eligible. To decrease the bias of including participants that may be incorrectly diagnosed with CLI, review authors defined CLI as persistently recurring ischaemic rest pain requiring regular analgesia for more than two weeks, or ulceration or gangrene of the foot or toes, attributable to objectively proven arterial occlusive disease by measurement of ankle pressure of < 50 mmHg or toe pressure < 30 mmHg. We defined non-reconstructable PAD as a resting ankle brachial index (ABI) < 0.9 when no reasonable open surgical or endovascular revascularisation treatment option is available, as determined by individual trial vascular specialists. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies identified for potential inclusion in the review. We planned to conduct data collection and analysis in accordance with the Cochrane Handbook for Systematic Review of Interventions. MAIN
RESULTS: We identified no studies that met the predefined inclusion criteria. To decrease the bias of including participants who may be incorrectly diagnosed with CLI, we based our inclusion criteria on objective tests, as described above. The randomised trials identified by the literature search were performed before such objective criteria for selection were applied and therefore were not eligible for inclusion in the review. AUTHORS'
CONCLUSIONS: We identified no RCTs assessing effects of lumbar sympathectomy by open, laparoscopic and percutaneous methods compared with no treatment or compared with any other method of lumbar sympathectomy in patients with CLI due to non-reconstructable PAD. High-quality studies are needed.

Entities:  

Mesh:

Year:  2016        PMID: 27959471      PMCID: PMC6463847          DOI: 10.1002/14651858.CD011519.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  32 in total

Review 1.  Antiplatelet agents for intermittent claudication.

Authors:  Peng F Wong; Lee Yee Chong; Dimitris P Mikhailidis; Peter Robless; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

Review 2.  Second European Consensus Document on chronic critical leg ischemia.

Authors: 
Journal:  Eur J Vasc Surg       Date:  1992-05

Review 3.  Systematic review of guidelines on peripheral artery disease screening.

Authors:  Bart S Ferket; Sandra Spronk; Ersen B Colkesen; M G Myriam Hunink
Journal:  Am J Med       Date:  2011-11-11       Impact factor: 4.965

4.  Dermofluorography as a possibility for therapeutic control following sympathectomy.

Authors:  U Böhler; V Wienert
Journal:  Int J Microcirc Clin Exp       Date:  1996 Jul-Aug

5.  Lumbar sympathectomy and arteriovenous shunting.

Authors:  J H Scarpino; J P Delaney
Journal:  Surg Forum       Date:  1971

Review 6.  [Effectiveness of lumbar sympathectomy in the treatment of occlusive peripheral vascular disease in lower limbs: systematic review].

Authors:  Jesús Ruiz-Aragón; Soledad Márquez Calderón
Journal:  Med Clin (Barc)       Date:  2009-12-21       Impact factor: 1.725

Review 7.  Exercise for intermittent claudication.

Authors:  G C Leng; B Fowler; E Ernst
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 8.  The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction.

Authors:  Iraklis I Pipinos; Andrew R Judge; Joshua T Selsby; Zhen Zhu; Stanley A Swanson; Aikaterini A Nella; Stephen L Dodd
Journal:  Vasc Endovascular Surg       Date:  2007 Dec-2008 Jan       Impact factor: 1.089

Review 9.  Lumbar sympathectomy techniques for critical lower limb ischaemia due to non-reconstructable peripheral arterial disease.

Authors:  Veena Kl Karanth; Tulasi Kota Karanth; Laxminarayan Karanth
Journal:  Cochrane Database Syst Rev       Date:  2016-12-13

Review 10.  Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non-reconstructable peripheral arterial disease.

Authors:  Indrani Sen; Sunil Agarwal; Prathap Tharyan; Rachel Forster
Journal:  Cochrane Database Syst Rev       Date:  2018-04-16
View more
  7 in total

1.  Lumbar sympathectomy can improve symptoms associated with ischaemia, vasculitis, diabetic neuropathy and hyperhidrosis affecting the lower extremities-a single-centre experience.

Authors:  Sean C Maguire; Christina A Fleming; Gavin O'Brien; Gerald McGreal
Journal:  Ir J Med Sci       Date:  2018-03-07       Impact factor: 1.568

Review 2.  Lumbar sympathectomy techniques for critical lower limb ischaemia due to non-reconstructable peripheral arterial disease.

Authors:  Veena Kl Karanth; Tulasi Kota Karanth; Laxminarayan Karanth
Journal:  Cochrane Database Syst Rev       Date:  2016-12-13

Review 3.  Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non-reconstructable peripheral arterial disease.

Authors:  Indrani Sen; Sunil Agarwal; Prathap Tharyan; Rachel Forster
Journal:  Cochrane Database Syst Rev       Date:  2018-04-16

Review 4.  Therapeutic Alternatives in Diabetic Foot Patients without an Option for Revascularization: A Narrative Review.

Authors:  Gerhard Ruemenapf; Stephan Morbach; Martin Sigl
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

5.  Systematic review of pharmacological therapies for the management of ischaemic pain in patients with non-reconstructable critical limb ischaemia.

Authors:  Áine Ní Laoire; Fliss E M Murtagh
Journal:  BMJ Support Palliat Care       Date:  2017-08-23       Impact factor: 3.568

6.  Perioperative patient-controlled regional analgesia versus patient-controlled intravenous analgesia for patients with critical limb ischaemia: a study protocol for a randomised controlled trial.

Authors:  Si Chen; Zhonghuang Xu; Hongju Liu; Yuelun Zhang; Jiao Zhang; Yuexin Chen; Yuehong Zheng; Yuguang Huang
Journal:  BMJ Open       Date:  2020-10-08       Impact factor: 2.692

7.  Segmental branches emanating from saphenous nerve morphing into sympathetic trunks for innervation of saphenous artery and its clinical implication for arterial sympathectomy.

Authors:  Yun Xie; Fang Fang; Peisen Lin; Zhiming Zhang; Yuehong Zhuang
Journal:  Int Wound J       Date:  2021-06-04       Impact factor: 3.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.